Chordate participates in Feminvest’s investor conference in Stockholm on October 8th

Chordate Medical non-executive Director and main owner Caroline Lundgren Brandberg will participate in Feminvest's investor conference "Fearless" in Stockholm on October 8th. She will take part in a panel discussion on entrepreneurship within publicly traded companies and growth in the life science sector.

“We participated in Fearless in Oslo earlier this year and received very positive response both on the Ozilia treatment method and the investment case itself. Feminvest represents a broad and strong network of investors with a particular focus on femtech and life science, where Chordate and Ozilia are a good fit given that migraine is a condition that primarily affects women,” says Caroline Lundgren Brandberg, board member of Chordate Medical.

Feminvest is an acceleration network for female ownership through education, as well as an investment operation. It is currently the largest platform for female investors and entrepreneurs in the Nordics, with nearly 47,000 subscribers. Feminvest also manages a network of 300 female angel investors.

“Over the past year, we have increased our efforts to raise awareness of the company and Ozilia both among potential investors and in segments surrounding Life Science. Feminvest covers both of these groups, making it a particularly suitable forum for us,” says Anders Weilandt, CEO of Chordate.

Caroline Lundgren Brandberg, MSc. in Engineering Physics, eMBA, has been a board member of Chordate Medical since 2021. Caroline is the Global Sales Director at climate-tech company Deedster and has previously worked internationally for Ericsson in various senior roles focusing on sales and marketing. She also holds several board and advisory board positions, including at Stockholm University.

Fearless Stockholm 2024 October Edition
October 8th, 2024
Musikaliska Kvarteret, Nybrokajen 11, Stockholm
Read more: https://feminvest.se/en/event/fearless-stockholm/

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact